These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 12963622

  • 1. Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer.
    Subramanian PS, Kerrison JB, Calvert PC, Miller NR.
    Arch Ophthalmol; 2003 Sep; 121(9):1335-6. PubMed ID: 12963622
    [No Abstract] [Full Text] [Related]

  • 2. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma.
    Phillips PM, Newman SA.
    Arch Ophthalmol; 2008 Jan; 126(1):137-9. PubMed ID: 18195236
    [No Abstract] [Full Text] [Related]

  • 3. Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer.
    Seth A, Anderson DP, Albiani DA, Barton JJ.
    Can J Ophthalmol; 2009 Aug; 44(4):467-8. PubMed ID: 19606178
    [No Abstract] [Full Text] [Related]

  • 4. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO.
    J Clin Oncol; 2003 Dec 01; 21(23):4277-84. PubMed ID: 14581438
    [Abstract] [Full Text] [Related]

  • 5. Bisphosphonates for men with prostate cancer: sifting through the rubble.
    Kelly WK, Steineck G.
    J Clin Oncol; 2003 Dec 01; 21(23):4261-2. PubMed ID: 14581442
    [No Abstract] [Full Text] [Related]

  • 6. Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.
    Missotten G, Verheezen Y.
    Bull Soc Belge Ophtalmol; 2010 Dec 01; (315):23-4. PubMed ID: 21110506
    [Abstract] [Full Text] [Related]

  • 7. Metronomic scheduling of anticancer agents for a refractory orbital pseudotumor in a child.
    Elhoudzi J, Rome A, Padovani L, Gentet JC, André N.
    J Pediatr Hematol Oncol; 2013 Nov 01; 35(8):632-3. PubMed ID: 23042015
    [No Abstract] [Full Text] [Related]

  • 8. Safety of long-term administration of bisphosphonates in elderly cancer patients.
    Tralongo P, Repetto L, Di Mari A, Mauceri G, Bollina R, Ferrau' F, Conti G.
    Oncology; 2004 Nov 01; 67(2):112-6. PubMed ID: 15539914
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of bisphosphonates in the treatment of prostate cancer.
    Olson KB, Pienta KJ.
    Oncology (Williston Park); 2000 Sep 01; 14(9):1361-4; discussion 1364-7. PubMed ID: 11033832
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases.
    Gaines KK.
    Urol Nurs; 2002 Dec 01; 22(6):398-400. PubMed ID: 12593231
    [No Abstract] [Full Text] [Related]

  • 16. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H, Tanaka T, Kuratsukuri K, Uchida J, Sugimura K, Tamada S, Nishisaka N, Kumata K, Iwai Y, Ikemoto S, Ezaki K, Nakatani T.
    Urol Int; 2007 Dec 01; 78(4):345-50. PubMed ID: 17495494
    [Abstract] [Full Text] [Related]

  • 17. Skeletal complications and the use of bisphosphonates in metastatic prostate cancer.
    Drudge-Coates L.
    Int J Palliat Nurs; 2006 Oct 01; 12(10):462-9. PubMed ID: 17167378
    [Abstract] [Full Text] [Related]

  • 18. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.
    Janssen van Doorn K, Neyns B, Van der Niepen P, Verbeelen D.
    Nephron; 2001 Dec 01; 89(4):467-8. PubMed ID: 11721169
    [No Abstract] [Full Text] [Related]

  • 19. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
    Miki T, Okihara K.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():632-5. PubMed ID: 18161177
    [No Abstract] [Full Text] [Related]

  • 20. Osteonecrosis of the jaw in a patient receiving bisphosphonate therapy.
    Reilly MM.
    Oncol Nurs Forum; 2007 Mar 28; 34(2):301-5. PubMed ID: 17573291
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.